Patents by Inventor Yifat OREN

Yifat OREN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230142669
    Abstract: The present invention is directed to a method for inducing skipping of exon 24 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Further, treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 24 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator.
    Type: Application
    Filed: March 25, 2021
    Publication date: May 11, 2023
    Applicant: SpliSense Ltd.
    Inventors: Yifat OREN, Ofra BARCHAD-AVITZUR, Efrat OZERI-GALAI
  • Publication number: 20220220486
    Abstract: The present invention provides methods for treating Cystic Fibrosis (CF) and methods for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849+10 Kb C-to-T comprising the step of administering a pharmaceutical composition comprising synthetic oligonucleotides complementary to a region of the CFTR comprising the 3849+10 Kb C-to-T mutation oligonucleotides and a composition comprising one or more CFTR modifiers.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 14, 2022
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, SPLISENSE LTD.
    Inventors: Bat Sheva KEREM, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR
  • Publication number: 20220213479
    Abstract: The present invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, including compositions comprising the oligonucleotides, and uses thereof, such as for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849 +10 Kb C-to-T, optionally in combination with additional CF therapeutics.
    Type: Application
    Filed: May 5, 2020
    Publication date: July 7, 2022
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, SpliSense Ltd.
    Inventors: Bat Sheva KEREM, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR
  • Publication number: 20220064647
    Abstract: The present invention is directed to a method for treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 23, exon 24, or both, of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator, and a method of producing thereof.
    Type: Application
    Filed: March 29, 2020
    Publication date: March 3, 2022
    Applicant: SpliSense Ltd.
    Inventors: Yifat OREN, Ofra BARCHAD-AVITZUR, Efrat OZERI-GALAI
  • Publication number: 20220040219
    Abstract: The present invention is directed to a method for treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 23 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator, and a method of producing thereof.
    Type: Application
    Filed: March 29, 2020
    Publication date: February 10, 2022
    Applicants: SpliSense Ltd., THE HOSPITAL FOR SICK CHILDREN
    Inventors: Christine BEAR, Onofrio LASELVA, Steven MOLINSKI, Yifat OREN, Ofra AVITZUR-BARCHAD, Efrat OZERI-GALAI